Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure

Cost Effectiveness and Resource Allocation

Volumn 4, Issue , 2006, Pages

  Hessel, Franz P ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALBUMIN DIALYSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL COST; HUMAN; KAPLAN MEIER METHOD; LIVER FAILURE; MALE; OUTPATIENT CARE; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33750019323     PISSN: 14787547     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-4-16     Document Type: Article

References (24)

1. Boker KH: [Acute liver failure]. Internist (Berl) 2001, 42(4):545-54, 556-62.
2. Lee WM: Acute liver failure in the United States. Semin Liver Dis 2003, 23(3):217-226.
3. Bauer M, Winning J, Kortgen A: Liver failure. Curr Opin Anaesthesiol 2005, 18(2):111-116.
4. Sen S, Williams R, Jalan R: Emerging indications for albumin dialysis. Am J Gastroenterol 2005, 100(2):468-475.
5. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH: The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002, 26(2):103-110.
6. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Lohr M, Liebe S, Schareck W, Hopt UT, Schmidt R: Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999, 23(4):319-330.
7. Steiner C, Mitzner S: Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002, 22 Suppl 2:20-25.
8. Mitzner S, Klammt S, Stange J, Noldge-Schomburg GF, Schmidt R: [Extracorporeal blood purification in severe liver failure with the albumin dialysis MARS - impact on relevant intensive care parameters]. Anasthesiol Intensivmed Notfal/med Schmerzther 2005, 40(4):199-206.
9. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R: Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003, 38(1):24-31.
10. Hessel FP: Reimbursement of high-prized new emerging Medical Devices in a DRG-based Hospital Care System - The German Situation. Expert Reviews in Pharmacoeconomics and Outcomes Research 2005, 5:377-381.
11. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J: Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002, 36(4 Pt 1):949-958.
12. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Lohr JM, Liebe S, Emmrich J, Korten G, Schmidt R: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000, 6(3):277-286.
13. Hessel FP, Mitzner SR, Rief J, Gress S, Guellstorff B, Wasem J: Economic evaluation of MARS - preliminary results on survival and quality of life. Liver 2002, 22 Suppl 2:26-29.
14. Hessel FP, Mitzner SR, Rief J, Guellstorff B, Steiner S, Wasem J: Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease. Liver Int 2003, 23 Suppl 3:66-72.
15. Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B: [Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation]. Gesundheitswesen 2005, 67(10):736-746.
16. Glennie JL, Torrance GW, Baladi JF, Berka C, Hubbard E, Menon D, Otten N, Riviere M: The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics 1999, 15(5):459-468.
17. Gold MR, Siegel JE, Russell LB, Weinstein MC: Cost-effectiveness in Health and Medicine. Oxford University Press, Oxford 1996.
18. CCOHTA: A Guidance Document for the costing process. CCOHTA, Ottawa 1996.
19. CCOHTA: Guidelines for economic evaluation of pharmaceuticals: Canada 2nd ed. CCOHTA, Ottawa 1997.
20. Bland JM, Altman DG: Survival Probabilities (the Kaplan-Meier method). British Medical Journal 1998, 317:1572.
21. Liu JP, Gluud LL, Als-Nielsen B, Gluud C: Artificial and bioartificial support systems for liver failure. Cochrane Database Syst Rev 2004:CD003628.
22. Rawlins MD, Culyer AJ: National Institute for Clinical Excellence and its value judgments. Bmj 2004. 329(7459):224-227.
23. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG: Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000, 20(3):332-342.
24. Khuroo MS, Khuroo MS, Farahat KL: Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004, 10(9):1099-1106.